Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities—Phase III Studies

Significant advances continue in the development of cancer-specific molecular imaging agents and modalities for diagnosing, staging, and treating various cancer types. For these advances to translate successfully to widespread clinical use, both regulatory approval by the U.S. Food and Drug